CMS to meet on beta amyloid PET imaging reimbursement
The Centers for Medicare & Medicaid Services (CMS) will convene a meeting Jan. 30, 2013, to review available evidence and hear public testimony on the use of beta amyloid PET imaging for the management of dementia and neurodegenerative disease.
The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) is interested in the clinical impact of this technology on health outcomes experienced by patients, according to the meeting announcement.
Currently, Medicare doesn’t cover beta amyloid PET imaging. Section 220.6 of the National Coverage Determination manual, which addresses coverage of PET, can be found here.
The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) is interested in the clinical impact of this technology on health outcomes experienced by patients, according to the meeting announcement.
Currently, Medicare doesn’t cover beta amyloid PET imaging. Section 220.6 of the National Coverage Determination manual, which addresses coverage of PET, can be found here.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.